Medisolv competitors

Steve Schelhammer is Chief Executive Officer at Phytel. The 25-year healthcare veteran is responsible for the company’s strategic direction and market positioning. His expertise in disease management is evident in his previous leadership positions. Before joining Phytel, Mr. Schelhammer founded Accordant Health Services, one of the country’s first disease management companies. The company grew to providing services for more than 500,000 people affected by complex chronic diseases. In 2000, he received the Ernst & Young Regional Entrepreneur of the Year Award for his work at Accordant. He also played a pivotal role in founding the Disease Management Association of America, where he was a charter member and served on its board for the first 3 years. Before founding Accordant, Mr. Schelhammer served as senior vice president at Quantum Health Resources, providing specialized home care services to people affected by rare chronic diseases. He also held upper management positions with other alternate site healthcare organizations including Care Partners, Tokos Medical Corporation and Caremark.

David Moatazedi is the President and Chief Executive Officer of Evolus (NASDAQ: EOLS). Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today.breakthrough products. David has nearly twenty years of commercial and executive experience building multiple market leading brands, including his most recent tenure as Senior Vice President of U.S. Medical Aesthetics at Allergan™ where he led the Medical aesthetic portfolio and several multi-billion-dollar acquisitions. David also currently sits on the board of Obalon Therapeutics (NASDAQ: OBLN). He holds an MBA in Marketing from Pepperdine University and a B.A. in Chemistry from California State University, Long Beach. David resides in Newport Beach with his wife and three children.